[Elsevier] DOI:10.1016/S0140‑6736(26)02026‑X

bushuang68 Post time Yesterday 14:45 | Show all posts |Read mode
This post will be closed automatically in 2026-11-01 14:43
Reward10points

DOI:10.1016/S0140‑6736(26)02026‑X
Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China
[size=1em]The Lancet
Date: Available online 26 October 2026


Reply

Use magic Donate Report

All Reply1 Show all posts
Sweetums33 Post time Yesterday 14:46 | Show all posts

Waiting for confirmation

If the PDF has not been accepted after 72 hours, the system will automatically adopt it.
Reply
bushuang68 Post time Yesterday 14:54 | Show all posts

Waiting for confirmation

If the PDF has not been accepted after 72 hours, the system will automatically adopt it.
Reply

Use magic Donate Report

Junior Member
  • post

  • reply

  • points

    70


Return to the list